MLTX
MoonLake Immunotherapeutics - Ordinary Shares - Class A

773
Loading...
Loading...
News
all
press releases
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
Zacks·4mo ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
Zacks·5mo ago
News Placeholder
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?
Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.
Stocktwits·8mo ago
News Placeholder
Buy Rating for MoonLake Immunotherapeutics Backed by Strong Prospects for Lead Candidate and Financial Stability
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on MoonLake Immunotherapeutics (MLTX Research Report). The associated p...
TipRanks Financial Blog·1y ago
News Placeholder
TimesSquare Capital Management LLC Has $23.44 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)
TimesSquare Capital Management LLC raised its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) by 1,270.7% in the 3rd quarter, according to the company in its most recent...
Ticker Report·2y ago
News Placeholder
MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the...
Globe Newswire·2y ago
News Placeholder
MoonLake Immunotherapeutics (NASDAQ:MLTX) Forecasted to Earn Q1 2024 Earnings of ($0.30) Per Share
MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) Analysts at HC Wainwright raised their Q1 2024 earnings estimates for MoonLake Immunotherapeutics in a note issued to investors...
Zolmax·2y ago
News Placeholder
HC Wainwright Weighs in on MoonLake Immunotherapeutics' Q1 2025 Earnings (NASDAQ:MLTX)
MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) HC Wainwright issued their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on...
Ticker Report·2y ago
News Placeholder
FY2028 Earnings Estimate for MoonLake Immunotherapeutics (NASDAQ:MLTX) Issued By Leerink Partnrs
MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) Stock analysts at Leerink Partnrs lifted their FY2028 earnings per share (EPS) estimates for shares of MoonLake...
Zolmax·2y ago
News Placeholder
Wedbush Reaffirms Outperform Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
Wedbush reissued their outperform rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm...
Zolmax·2y ago

Latest MLTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.